Nailujulian
Posted - 6 hours ago
$ATOS $AZN $LLY $NVS $PFE Some definitions I found for some of the big names involved in the data-release.
1.) "Contract" means a Funding Agreement that is a research and development contract that provides that the contractor perform for the benefit of the Government, with an expectation of completion of the stated research goals and the delivery of a report, data, materials or other product. Generally, Government
contracts are administered under the Federal Acquisition Regulations (FAR), codified at Title 48 Code of Federal Regulations, Chapter 1
2.) "Grant" means a Funding Agreement that is an award of financial assistance which may be provided for support of basic research in a specific field of interest to the funding Federal agency (See 45 CFR Part 74, for grants from the U.S. Public Health Service.) While no specific product is anticipated, the funding agency may review the progress and direction of the funded research.
rigpig
Posted - 7 hours ago
$ATOS - Main key people / companies involved at AACR meeting What do you think will be the outcome? $PFE $LLY $AZN $NVS https://www.abstractsonline.com/pp8/#!/20272/presentation/11540 Session PO.CT02.01 - Phase II Clinical Trials 1 CT205 / 5 - Neoadjuvant (Z)-endoxifen in premenopausal ER+, HER2- breast cancer: Evaluation of the first pharmacokinetic cohort of the EVANGELINE trial M. P. Goetz, Atossa Grant/Contract Pfizer Grant/Contract. Loxo at Lilly Grant/Contract, Travel, Other, consulting with Money to Mayo. Astra Zeneca Other, consulting with Money to Mayo. Novartis Other, consulting with Money to Mayo. Atossa theapeutics Employment. Atossa Therapeutics Grant/Contract. S. Quay, Atossa Therapeutics Employment, Stock, Other Business Ownership, Patent The only company with a patent - Atossa / Dr Quay Wish you all Happy Easter and a blessed year ahead
DharlMorey2
Posted - 10 hours ago
$ATOS (Reshare this to the newcomers) Quay says we having a data-driven year[1] -- timeline below from Samirsss. More DD on latest catalysts [2], and our pipeline is targeting before/during/after breast cancer which is unique (great acquisition target for $PFE, $AZN , etc.). Not much more I can say -- we're ready for a strong move up on data April 5th, and conference presentation April 10. Russell 2000/3000 inclusion possible soon on preliminary list release on 4/19. [1] https://www.genomeweb.com/Reprint-GW23002AtossaTherapeutics [2] https://www.proactiveinvestors.com/NASDAQ:ATOS/Atossa-Therapeutics-Inc [3] https://atossatherapeutics.com/product-pipeline/ I predict an $AMAM or $VKTX like move!
TheLionofwallstreet
Posted - 12 hours ago
$AVTX AIM IS NEXT! MICRO CAP BIO WORKING WITH $PFE $MRK $AZN BMY. 40 INTERNATIONAL PATENTS, 0 DEBT, GOOD DATA, GRANTS FROM THE NATIONAL CANCER INSTITUTE AND THE US DEPARTMENT OF DEFENSE. NEED I SAY MORE? OH YEA BLACKROCK AND VANGUARD HAVE LARGE HOLDINGS 🫡
stevie2times
Posted - 17 hours ago
$AIM add $AZN to that list w Imfinzi & Ampligen doing WORK vs Pan C solid tumors
MadM
Posted - 1 day ago
$PFE $MRK $AZN It's goods to be on drugs. And to think this all got started during Nancy Reagan's famous "Just say NO" initiative. (Monthly 'Drug Manufacture's Index.) I loved that "This is your brain, this is your brain on drugs." And the dude cracks an egg in a frying pan. He should have, for accuracy and on-message, said this is your brain on 'illegal' drugs maybe? What's the difference? Almost 10% of kids today are diagnosed with ADHD. That statistic comes from the CDC.
LVMN_Rocks
Posted - 1 day ago
$ABSI I’m here because these guys put their money where their mouths are,
$NVDA
$AZN
$MERK
$BMGF
@RKKG
And others. GL
FonsieTrader
Posted - 1 day ago
🚨 Actinium Pharmaceuticals (ATNM) Spearheading the Future of Oncology with Iomab-ACT's Innovative Clinical Trial $ATNM $AZN $BMY https://www.benzinga.com/pressreleases/24/03/ab37952759/actinium-pharmaceuticals-atnm-spearheading-the-future-of-oncology-with-iomab-acts-innovative-clin via @Benzinga TIC-TAC 🚨
StockInvest_us
Posted - 1 day ago
Signal alert: $AZN - GoldenStar https://stockinvest.us/l/liqhji6Jpj
DonCorleone77
Posted - 1 day ago
$AZN $SNY AstraZeneca, Sanofi announce Beyfortus approved in Japan AstraZeneca (AZN) and Sanofi's (SNY) Beyfortus, a long-acting monoclonal antibody, has been approved in Japan for the prophylaxis of lower respiratory tract disease, LRTD, caused by respiratory syncytial virus, RSV, in all neonates, infants and children entering their first RSV season, and the prevention of RSV LRTD in neonates, infants and children at risk of serious RSV infection entering their first or second RSV season. Beyfortus is anticipated to be available for the upcoming 2024/25 RSV season, in line with existing Japanese guidelines. Iskra Reic, Executive Vice President, Vaccines and Immune Therapies, AstraZeneca, said: "The approval of Beyfortus means it is possible for the first time to prevent serious respiratory disease due to RSV for all infants in Japan and reduce the infectious disease burden on healthcare systems. Beyfortus reflects AstraZeneca's commitment to the scientific development..."
DonCorleone77
Posted - 1 day ago
$AZN AstraZeneca's Truqap with Faslodex approved by Japanese MHLW AstraZeneca's Truqap in combination with Faslodex has been approved in Japan for the treatment of adult patients with unresectable or recurrent PIK3CA, AKT1, or PTEN-altered hormone receptor (HR)-positive, HER2-negative breast cancer following progression after treatment with endocrine therapy. The approval by the Japanese Ministry of Health, Labour, and Welfare, MHLW, was based on the results from the CAPItello-291 Phase III trial published in The New England Journal of Medicine. Dave Fredrickson, Executive Vice President, Oncology Business Unit, AstraZeneca, said: "Breast cancer is the most common cancer among women in Japan, and innovative, new treatment options are urgently needed. Today's approval of Truqap, a first-in-class AKT-inhibitor, represents a significant step forward for HR-positive breast cancer treatment and an important new option for approximately fifty per cent of patients...."
Chipwars
Posted - 1 day ago
$AZN Astrazeneca to manufacture in the US, EU AND China to pre-empt any DOJ / supply chain issues. Very smart : https://www.bloomberg.com/news/videos/2024-03-27/astrazeneca-ceo-soriot-on-pharmaceuticals-in-china-video
HUSA_TO_100
Posted - 3 days ago
$ATOS Don’t be surprised if this gets BO by some big pharma after its Phase 2 Data✅ $LABP got takeover by $ABBV today while $FUSN got acquired by $AZN a week ago. Bios are getting BO left and right by big Pharmas this year🔥
DharlMorey2
Posted - 3 days ago
$ATOS It seems $PFE has the most pressure to show investors new long term growth -- so I wouldn't be surprised if they took a flyer here. $AZN been the natural fit for a long time to update Tamoxifen. Still a good price to accumulate otherwise for $AMAM like movement! https://investors.atossatherapeutics.com/ (See slide 21 below: https://investors.atossatherapeutics.com/static-files/4ae72f7e-21f9-4deb-8af4-a02cff7c2dfd)
DoubleBank
Posted - 3 days ago
$AZN $BMY $PFE $NKGN news is awesome nkgn should rock
Dtwood7474
Posted - 3 days ago
$NKGN $PFE Honestly, I don't care if you are shorting, holding etc this stock. This is amazing news. This is great for the soul of any person that has had to deal with Alzheimer's in their family. So many improvements with this treatment, and zero adverse effects. I hope this is successful for all of those families. $AZN $BMY . This could rocket afterhours. https://finance.yahoo.com/news/nkgen-biotech-presents-additional-phase-200500597.html
HUSA_TO_100
Posted - 3 days ago
$ATOS Won’t be surprised if it gets BO by some big pharma after its Phase 2 Data✅ $LABP got takeover by $ABBV today while $FUSN got acquired by $AZN a week ago. Small Bios are getting BO left and right this year🔥
Teleboy
Posted - 3 days ago
$AIM Weekly update: Yet another week with positive news Insider buying from three directors and the COO. Excellent interim data from the $AZN Pancreatic trial; other positive updates from TNBC, Melanoma, and Pancreatic trials. Waiting to hear: 1. Takeover/licensing negotiations progress. On Azenova LLC helping find a deal: "They're experts in moving drugs into oncology licensing agreement, and IF the people that we are working with now [ $MRK and $AZN] are not interested in moving forward, there are other companies that may be interested. 2. UPitt ovarian cancer data update due Q1 Ampligen with Keytruda $MRK NCT03734692 (phase 1 and 2) 3. TNBC final trial results with Keytruda $MRK and Celebrex $PFE NCT03599453 (phase 1) 4. US pancreatic 1st dose
Chipwars
Posted - 3 days ago
$AZN Astrazeneca. This should go higher. FDA approval for another drug : https://www.sharecast.com/news/news-and-announcements/astrazeneca--16488934.html
DonCorleone77
Posted - 3 days ago
$AZN FDA approves AstraZeneca's Ultomiris for rare nerve disease NMOSD ULTOMIRIS or ravulizumab-cwvz, has been approved in the United States as the first and only long-acting C5 complement inhibitor for the treatment of adult patients with anti-aquaporin-4 AQP4 antibody-positive Ab+ neuromyelitis optica spectrum disorder NMOSD . The approval by the US Food and Drug Administration FDA was based on positive results from the CHAMPION-NMOSD Phase III trial, which were published in the Annals of Neurology. In the trial, ULTOMIRIS was compared to an external placebo arm from the pivotal SOLIRIS PREVENT clinical trial. ULTOMIRIS met the primary endpoint of time to first on-trial relapse as confirmed by an independent adjudication committee. Zero relapses were observed among ULTOMIRIS patients with a median treatment duration of 73 weeks and recurrent and may result in permanent disability. The diagnosed prevalence of adults with NMOSD in the US is estimated at approximately 6,000.9-11...
DonCorleone77
Posted - 3 days ago
$AZN AstraZeneca reports Ultomiris approved in U.S. for adults with NMOSD Ultomiris has been approved in the United States as "the first and only long-acting C5 complement inhibitor" for the treatment of adult patients with anti-aquaporin-4 antibody-positive neuromyelitis optica spectrum disorder, or NMOSD, AstraZeneca announced. Ultomiris is also approved for certain adults with NMOSD in Japan and the European Union. Regulatory reviews are ongoing in additional countries. Marc Dunoyer, Chief Executive Officer, Alexion, said: "Alexion has been at the forefront of innovation in NMOSD, striving to offer patients a future without fear of life-altering or even fatal relapses. Building on the established efficacy of C5 inhibition for people living with AQP4 Ab+ NMOSD, we are proud to deliver a transformative, long-acting treatment option that has the potential to eliminate relapses with a convenient dosing schedule every eight weeks....
Stock_Titan
Posted - 3 days ago
$AZN ULTOMIRIS® (ravulizumab-cwvz) approved in the US for the treatment of adults with neuromyelitis optica spectrum disorder (NMOSD)
https://www.stocktitan.net/news/AZN/ultomiris-r-ravulizumab-cwvz-approved-in-the-us-for-the-treatment-of-p7oljn120si2.html
lonelywarrior
Posted - 5 days ago
@OptionWheel You're welcome! The recent $FUSN acquisition by $AZN is another evidence.
Skywalker86
Posted - 6 days ago
$SPY $AZN